modelOtherPreparationsCombina
Extends from Pharmacolibrary.Drugs.ATC.C.C05AX03.
Information
| name: | OtherPreparationsCombinations | |
| ATC code: | C05AX03 | route: | topical |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 10 | L |
| clearance: | 1 | L/h |
| other parameters in model implementation | ||
The ATC group C05AX03 refers to combination preparations used as vasoprotectives for treatment of hemorrhoids and varicose veins, often formulated as topical creams, ointments, or suppositories containing various agents such as corticosteroids, anesthetics, and vasoconstrictors. These are primarily used for symptomatic relief of hemorrhoids and are still in use today in several countries, though specific formulations may differ.
Pharmacokinetics
No direct published pharmacokinetic data available for unspecified combination preparations under ATC code C05AX03; values estimated based on typical topical administration of combination hemorrhoidal agents in adults.
References
Abdalla, MI, & Herfarth, H (2016). Budesonide for the treatment of ulcerative colitis. Expert opinion on pharmacotherapy 17(11) 1549–1559. DOI:10.1080/14656566.2016.1183648 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27157244
Gilani, SJ, et al., & Imam, SS (2018). Nano-Based Therapy for Treatment of Skin Cancer. Recent patents on anti-infective drug discovery 13(2) 151–163. DOI:10.2174/1574891X13666180911095440 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30205801
Lin, YS, et al., & Milgrom, P (2018). Pharmacokinetics of Iodine and Fluoride following Application of an Anticaries Varnish in Adults. JDR clinical and translational research 3(3) 238–245. DOI:10.1177/2380084418771930 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30938600
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)